Monocyte/macrophage-mediated venous thrombus resolution

Front Immunol. 2024 Jul 19:15:1429523. doi: 10.3389/fimmu.2024.1429523. eCollection 2024.

Abstract

Venous thromboembolism (VTE) poses a notable risk of morbidity and mortality. The natural resolution of the venous thrombus might be a potential alternative treatment strategy for VTE. Monocytes/macrophages merge as pivotal cell types in the gradual resolution of the thrombus. In this review, the vital role of macrophages in inducing inflammatory response, augmenting neovascularization, and facilitating the degradation of fibrin and collagen during thrombus resolution was described. The two phenotypes of macrophages involved in thrombus resolution and their dual functions were discussed. Macrophages expressing various factors, including cytokines and their receptors, adhesion molecules, chemokine receptors, vascular endothelial growth factor receptors, profibrinolytic- or antifibrinolytic-related enzymes, and other elements, are explored for their potential to promote or attenuate thrombus resolution. Furthermore, this review provides a comprehensive summary of new and promising therapeutic candidate drugs associated with monocytes/macrophages that have been demonstrated to promote or impair thrombus resolution. However, further clinical trials are essential to validate their efficacy in VTE therapy.

Keywords: inflammation; macrophages; monocytes; neovascularization; thrombus resolution; venous thromboembolism.

Publication types

  • Review

MeSH terms

  • Animals
  • Humans
  • Macrophages* / immunology
  • Macrophages* / metabolism
  • Monocytes* / immunology
  • Monocytes* / metabolism
  • Venous Thromboembolism / drug therapy
  • Venous Thromboembolism / immunology
  • Venous Thromboembolism / pathology
  • Venous Thrombosis* / immunology
  • Venous Thrombosis* / metabolism

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by grants from the National Natural Science Foundation of China (Nos. 81973551), the Science and Technology Commission of Shanghai Municipality (Nos. 21ZR1460400), the Health Commission of Shanghai Municipality (ZY (2021–2023)-0203-04), Future Plan for Traditional Chinese Medicine Inheritance and Development of Shanghai Municipal Hospital of Traditional Chinese Medicine (WLJH2021ZY-ZYY007; WL-HBBD-2021001K).